Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Comparision between Trident Texofab IPO and Vanta Bioscience IPO.
Trident Texofab IPO is a SME Fixed Price Issue IPO proposed to list at BSE SME while Vanta Bioscience IPO is a SME Fixed Price Issue proposed to list at BSE SME.
| Trident Texofab IPO | Vanta Bioscience IPO | |
|---|---|---|
| Logo |  |
 |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Fixed Price Issue | Fixed Price Issue |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Guiness Corporate Advisors Pvt Ltd | Inventure Merchant Banker Services Pvt Ltd |
| Registrar | Kfin Technologies Limited | Bigshare Services Pvt Ltd |
| Market Maker | ||
| DRHP | DRHP  |
|
| RHP | RHP |
|
| Anchor Investor | ||
| IPO Allotment URL |
The total issue size of Trident Texofab IPO is up to ₹3.53 Cr whereas the issue size of the Vanta Bioscience IPO is up to ₹7.56 Cr. The final issue price of Trident Texofab IPO is ₹30.00 per share and of Vanta Bioscience IPO is ₹50.00 per share.
| Trident Texofab IPO | Vanta Bioscience IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ₹30.00 per share | ₹50.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 4000 shares | 3000 shares |
| Fresh Issue Size | ||
| Fresh Issue Size (Amount) | ||
| OFS Issue Size | ||
| OFS Issue Size (Amount) | ||
| Issue Size Total | 11,76,000 shares | 15,12,000 shares |
| Issue Size Total (Amount) | up to ₹3.53 Cr | up to ₹7.56 Cr |
Trident Texofab IPO opens on Sep 21, 2017, while Vanta Bioscience IPO opens on Sep 25, 2017. The closing date of Trident Texofab IPO and Vanta Bioscience IPO is Sep 26, 2017, and Sep 27, 2017, respectively.
| Trident Texofab IPO | Vanta Bioscience IPO | |
|---|---|---|
| Anchor Bid Date | ||
| Issue Open | Sep 21, 2017 | Sep 25, 2017 |
| Issue Close | Sep 26, 2017 | Sep 27, 2017 |
| Basis Of Allotment (Tentative) | ||
| Initiation of Refunds (Tentative) | ||
| Credit of Share (Tentative) | ||
| Listing date (Tentative) | ||
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
Trident Texofab IPO P/E ratio is , as compared to Vanta Bioscience IPO P/E ratio of .
| Trident Texofab IPO | Vanta Bioscience IPO | |
|---|---|---|
| Financial | ||
| Promoter Shareholding (Pre-Issue) | ||
| Promoter Shareholding (Post-Issue) | ||
| P/E Ratio | ||
| Market Cap | ||
| ROE | ||
| ROCE | ||
| Debt/Equity | ||
| EPS | ||
| RoNW |
In the Trident Texofab IPO retail investors (RII) are offered while in Vanta Bioscience IPO retail investors are offered . Qualified institutional buyers (QIB) are offered in Trident Texofab IPO and in Vanta Bioscience IPO.
| Trident Texofab IPO | Vanta Bioscience IPO | |
|---|---|---|
| Anchor Investor Reserveration | ||
| Market Maker Reserveration | ||
| QIB | ||
| NII | ||
| RII | ||
| Employee | ||
| Others | ||
| Total |
Trident Texofab IPO subscribed in total, whereas Vanta Bioscience IPO subscribed .
| Trident Texofab IPO | Vanta Bioscience IPO | |
|---|---|---|
| QIB (times) | ||
| NII (times) | ||
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | ||
| Employee (times) | ||
| Other (times) | ||
| Total (times) |
Add a public comment...
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
